Novo Nordisk shares fall on pricing doubts despite CagriSema trial win
US-listed shares dropped more than 4% premarket as analysts questioned the company's pricing power and dealmaking ahead of Wegovy's post-2030 patent expiry.
TR
By Tom Reyes · Markets Editor
Sep 21 10:02 ETSource: NDTV Profit
The wire
- 01Novo's US-listed stock fell more than 4% premarket after it reported CagriSema at 1 mg beat tirzepatide 5 mg on weight loss, 12.4% versus 9.1%, in a late-stage diabetes trial.
- 02BMO analyst Evan Seigerman said the low-dose result is blunted because tirzepatide previously outperformed higher CagriSema doses in obesity; an earlier head-to-head against Zepbound missed.
- 03Novo used its capital markets day to lay out a multi-year obesity injectable plan targeting a CagriSema launch early next year, with an FDA decision due in the fourth quarter.
From the source
Read at ndtvprofit.comNovo Shares Plunge 6% Despite CagriSema Beating Lilly In Diabetes Trial
Novo Nordisk has revealed that its experimental next-generation drug, CagriSema, led to an estimated average weight loss of 12.4% in a late-stage trial for type 2 diabetes patients, surpassing Eli Lilly's competing medication, according to a report.
